ClinicalTrials.gg
Not yet recruitingNCT07939113CARE-NETUpdated Nov 16, 2026

Real-World Effectiveness of Cabozantinib in Advanced Neuroendocrine Tumors: A Retrospective Multicenter Study Using the GTE-RENATEN National Database

An observational study in Advanced Neuroendocrine Carcinoma, sponsored by Hospices Civils de Lyon. Not yet recruiting at 1 site in France. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Hospices Civils de Lyon · Observational

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
150
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 60 studies in Neuroendocrine Tumors with a site in France — 19 open to participants now, 26 under way, 8 of them phase 3. Neuroendocrine Tumors · France.

Planned enrollment
8th of 20
150 · median 118
Started
2026
with 1 other
Observational
20 of 60
6 open now
Primary completion
2027-01
later than 9 of 25 live
Registered
60th of 60
by date
Lead sponsor
5 of 60
Hospices Civils de Lyon

Among the 60 studies in Neuroendocrine Tumors with a site in France, this one is the 8th largest by planned enrollment of the 20 observational ones that give a count, is one of 2 that started in 2026, is one of 20 observational ones, reaches primary completion later than 9 of the 25 other live ones, and was the 60th registered.

Neuroendocrine Tumors

543 studies on the registry are indexed under Neuroendocrine Tumors; 135 are open to participants now.

Browse Neuroendocrine Tumors studies →

Open to participants now

19 of the 60 studies in Neuroendocrine Tumors with a site in France are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 112 Neuroendocrine Tumors studies recruiting now, 73 (65%) set no upper age limit and 17 (15%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies in Neuroendocrine Tumors with a site in France, or all of them as a file.
02

Study summary

Neuroendocrine tumors are rare tumors with prolonged survival. The management of patients at advanced stage is centered on both locoregional control and systemic therapy. Systemic approaches include somatostatin analogs (SSA) that improve symptom control and slow tumor progression, peptide receptor radionuclide therapy (PRRT), targeted agents (everolimus, sunitinib and cabozantinib) and chemotherapy. All these therapies have demonstrated clinical benefit across multiple randomized and non-randomized studies, yet no high-level evidence defines the optimal sequence in which they should be administered in real-world metastatic settings.

The recent approval of cabozantinib, a multikinase inhibitor targeting VEGFR, MET, and AXL, represents a major advancement in the systemic management of NETs.

The retrospective study "CARE-NET", is a multicenter study which has the aims to describe the real-world use of cabozantinib (between January 2020 and August 2026) in France.

03

Conditions studied

  • Advanced Neuroendocrine Carcinoma

Browse trials for

Keywords

  • Neuroendocrine tumors
  • Cabozantinib
  • Sequence
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The study aims to enroll approximately 150 patients which initiate cabozantinib between January 2020 and August 2026 across participating centers.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults ≥18 years.
  • confirmed, well-differentiated NET (G1-G3) or typical/atypical thoracic carcinoids
  • or unresectable disease.
  • Cabozantinib initiated between January 2020 and August 2026.

Exclusion criteria

Exclusion Criteria:

  • Poorly differentiated neuroendocrine carcinoma (NEC), including MiNEN with NEC component.
  • Missing data for the cabozantinib: date of start or date of stop
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
150 participants (estimated)
Patient registry
No

Groups and cohorts

  • Advanced Neuroendocrine Tumors treated by cabozantinib follow in ENDOCAN RENATEN network

    Adults ≥18 years. Histologically confirmed, well-differentiated NET (G1-G3) or typical/atypical thoracic carcinoids Metastatic or unresectable disease. Cabozantinib initiated between January 2020 and August 2026

06

What researchers measure

Primary outcomes

  1. To evaluate, in real-world clinical practice, the Disease Control Rate (DCR) achieved with cabozantinib among patients with advanced or metastatic well-differentiated NETs treated between January 2020 and August 2026.

    This primary objective will be evaluated in the intention-to-treat population and in the "evaluable population" defined that patient who received at least one month of treatment (time between first and last dose of cabozantinib) and with an available imaging at least 2 months after the beginning of cabozantinib in order to assess the morphological change according to RECIST criteria 1.1.

    Time frame: Retrospective data between January 2020 and August 2026

07

Study locations

1 site
  • Hospices Civils de Lyon, Medical Oncology Department, Edouard Herriot Hospital
    Lyon, 69003, France
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2026; primary completion for Jan 2027, 1 month later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 16, 2026
StartEst.
Dec 2026
Primary completionEst.
Jan 2027
CompletionEst.
Jan 7, 2028
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07939113
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
Dec 2026 (estimated)
Primary completion
Jan 2027 (estimated)
Completion
Jan 7, 2028 (estimated)
Last update
Nov 16, 2026

Study contacts

thomas T walter, MD
Contact
thomas.walter@chu-lyon.fr
4 72 11 00 94 ext. 0033
galina JEPIRAL
Contact
groupetumeursendocrines@gmail.com
1 42 11 42 11 ext. 0033

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion